Traci Beck, MD
Urogynecology and Reconstructive Pelvic Surgery · Chicago, ILNPI 1710963749
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Astellas Pharma US Inc at 53.9% of the total. Reporting peaked in 2019 at $11,254 and has fallen 95.7% since, to $482 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $265.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$17K
- Urovant Sciences Inc$10K
- Boston Scientific$2K
- Axonics, Inc.$1K
- AbbVie$678
- Medtronic$423
- plus $1K from 17 others
What the payments were for
- Consulting fees$4,95015%
- Speaking & faculty fees$17,49554%
- Travel & lodging$4,33713%
- Food & beverage$5,53117%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 24 | $17,430 |
| Urovant Sciences Inc | 15 | $9,676 |
| Boston Scientific | 27 | $1,669 |
| Axonics, Inc. | 11 | $1,335 |
| AbbVie(2 entities) | 15 | $678 |
| Medtronic(2 entities) | 8 | $423 |
| Bluewind Medical | 3 | $263 |
| Femselect Inc. | 2 | $171 |
| Laborie Medical Technologies Corp. | 1 | $125 |
| Novo Nordisk | 1 | $122 |
| Olympus America Inc. | 1 | $99 |
| Acessa Health Inc. | 1 | $75 |
| Astellas Pharma Global Development | 2 | $63 |
| Myriad Genetic Laboratories, Inc. | 2 | $37 |
| Sumitomo Pharma America, Inc. | 1 | $34 |
| Gilead | 1 | $26 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Gynesonics, Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Merck | 1 | $19 |
| Pfizer | 1 | $19 |
| Amgen | 1 | $17 |
| Minerva Surgical, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$12,116
- GEMTESA$9,401
- Axonics$1,094
- BOTOX$373
- REVI$262
- INTERSTIM$234
- Solyx SIS System$164
- Bulkamid$164
- EnPlace$147
- GENERAL ERECTILE DYSFUNCTION$142
- LithoVue$134
- GENERAL MALE SUI$125
- XENFORM$125
- Ozempic$122
- GENERAL PELVIC ORGAN PROLAPSE$111
How this compares
$32,365 in reported general payments places this provider in the 90th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
See all urogynecology and reconstructive pelvic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 74 | $83,437 |
| MyrbetriqMirabegron | 91 | $83,255 |
| PremarinEstrogens, Conjugated | 15 | $6,386 |
| Solifenacin Succinate | 50 | $2,636 |
| Tamsulosin Hcl | 69 | $2,101 |
| Estradiol | 30 | $1,906 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 23 | $632 |
| Finasteride | 32 | $556 |
| Oxybutynin Chloride ErOxybutynin Chloride | 25 | $407 |
| Cephalexin | 14 | $261 |
| Ciprofloxacin Hcl | 21 | $94 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $34 | $83,43774 claims |
| Astellas Pharma US IncMyrbetriq | $17,430 | $83,25591 claims |
| PfizerPremarin | $19 | $6,38615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
Other urogynecology and reconstructive pelvic surgery in Chicago
- Abraham ShashouaChicago$339K
- Akira GillinghamChicago$58K
- Kimberly KentonChicago$43K
- Margaret MuellerChicago$26K
- Carol BretschneiderChicago$14K
- Trieu DoChicago$11K
- Sean GeorgeChicago$9K
- Thythy PhamChicago$8K
- Ankita GuptaChicago$7K
- Sarah AdelsteinChicago$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.